4D Molecular Therapeutics Inc (NASDAQ: FDMT) on Monday, plunged -8.72%% from the previous trading day, before settling in for the closing price of $4.13. Within the past 52 weeks, FDMT’s price has moved between $2.23 and $28.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -9.89% annually for the last half of the decade. The company achieved an average annual earnings per share of -19.97%. With a float of $41.55 million, this company’s outstanding shares have now reached $46.32 million.
In an organization with 227 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 17811.11%, operating margin of -2259177.78%, and the pretax margin is -1960433.33%.
4D Molecular Therapeutics Inc (FDMT) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of 4D Molecular Therapeutics Inc is 10.31%, while institutional ownership is 88.02%. The most recent insider transaction that took place on Sep 16 ’24, was worth 8,165. In this transaction Chief Legal Officer of this company sold 500 shares at a rate of $16.33, taking the stock ownership to the 6,781 shares. Before that another transaction happened on Aug 19 ’24, when Company’s Chief Legal Officer sold 500 for $15.00, making the entire transaction worth $7,500. This insider now owns 6,781 shares in total.
4D Molecular Therapeutics Inc (FDMT) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -19.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.31% during the next five years compared to -9.89% drop over the previous five years of trading.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
4D Molecular Therapeutics Inc (FDMT) is currently performing well based on its current performance indicators. A quick ratio of 12.36 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8732.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.37, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -3.87 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Let’s dig in a bit further. During the last 5-days, its volume was 0.44 million. That was inferior than the volume of 0.69 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 7.18%.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 32.91%, which indicates a significant increase from 4.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 85.39% in the past 14 days, which was lower than the 91.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.57, while its 200-day Moving Average is $6.25. However, in the short run, 4D Molecular Therapeutics Inc’s stock first resistance to watch stands at $4.05. Second resistance stands at $4.33. The third major resistance level sits at $4.49. If the price goes on to break the first support level at $3.61, it is likely to go to the next support level at $3.45. The third support level lies at $3.17 if the price breaches the second support level.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
Market capitalization of the company is 174.64 million based on 46,325K outstanding shares. Right now, sales total 40 K and income totals -160,870 K. The company made 10 K in profit during its latest quarter, and -47,970 K in sales during its previous quarter.
